Revvity, Inc. ( (RVTY) ) has released its Q1 earnings. Here is a breakdown of the information Revvity, Inc. presented to its investors.
Revvity, Inc., a prominent player in the health science sector, specializes in providing comprehensive solutions from discovery to diagnosis, serving a diverse clientele across pharmaceuticals, biotech, and diagnostic labs globally. In its first quarter of 2025, Revvity reported a revenue of $665 million, marking a 2% increase from the previous year, with a GAAP earnings per share (EPS) of $0.35 and an adjusted EPS of $1.01. The company also reaffirmed its full-year guidance for organic growth and adjusted EPS.
Key financial highlights include a GAAP operating income of $72 million, up from $44 million the previous year, and an adjusted operating income of $170 million. The Life Sciences segment saw a slight revenue increase to $340 million, while the Diagnostics segment reported a revenue of $324 million, reflecting a 3% growth. The company’s adjusted operating profit margins remained robust, with Life Sciences at 31.1% and Diagnostics at 22.8%.
Revvity’s strategic focus on navigating the dynamic market environment has positioned it well for the remainder of the year. The company has raised its full-year revenue guidance to $2.83-$2.87 billion, reflecting changes in foreign currency exchange rates, and continues to project an organic growth rate of 3-5%.
Looking ahead, Revvity remains committed to adapting to the evolving macroeconomic landscape, leveraging its unique business strengths to drive continued growth and innovation in the health science sector.